PCS499
PCS499-NL01
Phase 2 small_molecule completed
Quick answer
PCS499 for Necrobiosis Lipoidica is a Phase 2 program (small_molecule) at Processa Pharmaceuticals with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Processa Pharmaceuticals
- Indication
- Necrobiosis Lipoidica
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed